Filing summary: Transgenomic, Inc. (10-Q, quarter ended March 31, 2012)
Entity note: The supplied filing is for Transgenomic, Inc., not Precipio, Inc. It reports the three months ended March 31, 2012, with comparisons to the same period in 2011. Financial amounts below are in U.S. dollars; unless stated otherwise, amounts are in millions.
Business context and financial results
Transgenomic operated three businesses: Clinical Laboratories, Pharmacogenomics Services, and Diagnostic Tools, including WAVE systems, other instruments, and consumables.
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Net sales | $7.206 | $7.480 |
| Gross profit / margin | $3.104 / 43% | $4.154 / 56% |
| Operating loss | $2.439 | $0.750 |
| Net loss | $2.696 | $2.778 |
| Net loss available to common stockholders | $2.861 | $3.038 |
| Basic and diluted loss per share | $0.05 | $0.06 |
| Operating cash flow | $(2.760) | $0.051 |
| Investing cash flow | $(0.265) | $(0.087) |
| Financing cash flow | $17.349 | $(0.307) |
Liquidity, debt, and capital
- Cash and cash equivalents were $19.291 million at March 31, 2012, up from $4.946 million at year-end 2011. Working capital was $15.413 million, versus $0.870 million at year-end.
- Total debt, based on current maturities and long-term debt shown on the balance sheet, was $8.639 million, compared with $11.722 million at December 31, 2011. The filing classifies $7.294 million as current maturities at quarter-end.
- In February, the company completed a private placement described as approximately $22 million, including $3 million of convertible notes converted into equity. Net proceeds were $17.4 million. It issued 19 million shares to investors and 3 million shares upon conversion of the notes; outstanding common shares were 71.646 million at March 31.
- The company reported a $3.1 million common-stock warrant liability, measured using Level 3 fair-value inputs. Preferred dividends accrued during the quarter were $0.165 million.
Material changes and management commentary
- Sales fell 4% year over year. Clinical Laboratories sales declined 3% to $3.371 million; management attributed lower throughput and revenue partly to a software failure in the New Haven laboratory information management system (LIMS). The company said capacity had been restored and expected to clear the resulting backlog by June 2012.
- Pharmacogenomics Services sales increased 133% to $0.630 million, but management cautioned that clinical-trial activity and specimen timing can make quarterly revenue variable.
- Diagnostic Tools sales declined 14% to $3.205 million. Instrument unit sales increased, including nine WAVE instruments versus four a year earlier, but lower average instrument pricing and weaker bioconsumables sales reduced revenue and margin.
- Gross margin weakened in Clinical Laboratories (38% versus 54%) and Diagnostic Tools (45% versus 64%); Pharmacogenomics Services improved to 59% from negative 42%. SG&A rose to $4.994 million from $4.323 million, including $0.474 million in doubtful-account provision and $0.273 million in stock-based compensation.
Outlook, risks, and contingencies
- Management anticipated continued 2012 growth across all three business units, citing new and in-licensed assays, international expansion, and product development. No quantified revenue, earnings, or cash-flow guidance was provided.
- The company said its $19.3 million cash balance and available liquidity were sufficient for expected needs in 2012 and beyond, while also warning that it historically operated at a loss and may not be able to increase sales, reduce expenses, or raise additional capital indefinitely.
- A financing-related provision requires a $5.5 million prepayment to PGxHealth under a senior secured promissory note. The company said it had not received a response to its attempts to coordinate payment and intended to comply with the note’s terms; it recorded the full amount as a current liability.
- Management identified potential risks from future LIMS or sample-processing disruptions, customer budget constraints and long instrument sales cycles, competition, reimbursement and regulatory factors, and foreign-exchange movements. The company did not hedge foreign currency exposure and stated that a hypothetical 10% exchange-rate change could materially affect future operating results.
- Ordinary-course claims were not expected by management to have a material adverse effect. Vendor commitments were $2.3 million; operating leases extend through 2022. The filing reported no material subsequent events and no off-balance-sheet arrangements.
Most important facts for investors to verify
- Confirm the issuer: this filing identifies Transgenomic, Inc.; the request metadata names Precipio, Inc.
- Review the $5.5 million PGxHealth prepayment obligation, its payment timing and terms, and how it affects near-term liquidity.
- Track operating cash burn against the financing proceeds and management’s liquidity assumptions.
- Check whether LIMS performance and the sample backlog were resolved as expected, and whether laboratory margins recovered.
- Assess whether Diagnostic Tools consumables demand and segment margins improved, and whether pharmacogenomics trial revenue proved sustainable.
- Review dilution from the share issuance and outstanding warrants, as well as changes in the $3.1 million warrant liability.